These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22110541)

  • 1. Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases.
    Takakubo Y; Konttinen YT
    Clin Dev Immunol; 2012; 2012():941346. PubMed ID: 22110541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases.
    Rutella S; De Cristofaro R; Ferraccioli G
    Hum Immunol; 2009 May; 70(5):360-73. PubMed ID: 19405176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical aspects of autoimmune rheumatic diseases.
    Goldblatt F; O'Neill SG
    Lancet; 2013 Aug; 382(9894):797-808. PubMed ID: 23993190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.
    Moorman CD; Sohn SJ; Phee H
    Front Immunol; 2021; 12():657768. PubMed ID: 33854514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmunity in common variable immunodeficiency.
    Agarwal S; Cunningham-Rundles C
    Curr Allergy Asthma Rep; 2009 Sep; 9(5):347-52. PubMed ID: 19671377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells as targets or therapeutics in rheumatic autoimmune disease.
    Thomas R
    Curr Opin Rheumatol; 2014 Mar; 26(2):211-8. PubMed ID: 24389864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerogenic dendritic cells in cancer, transplantation, and autoimmune diseases.
    Suciu-Foca N; Berloco P; Cortesini R
    Hum Immunol; 2009 May; 70(5):277-80. PubMed ID: 19275919
    [No Abstract]   [Full Text] [Related]  

  • 8. Flow cytometric detection of p38 MAPK phosphorylation and intracellular cytokine expression in peripheral blood subpopulations from patients with autoimmune rheumatic diseases.
    Mavropoulos A; Bogdanos DP; Liaskos C; Orfanidou T; Simopoulou T; Zafiriou E; Sakkas LI; Rigopoulou EI
    J Immunol Res; 2014; 2014():671431. PubMed ID: 24741615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease.
    Baglaenko Y; Chang NH; Johnson SR; Hafiz W; Manion K; Ferri D; Noamani B; Bonilla D; Rusta-Sellehy S; Lisnevskaia L; Silverman E; Bookman A; Landolt-Marticorena C; Wither J
    Arthritis Res Ther; 2018 Nov; 20(1):264. PubMed ID: 30486869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion in autoimmune rheumatic diseases.
    Pitashny M; Shoenfeld Y
    Autoimmun Rev; 2005 Sep; 4(7):436-41. PubMed ID: 16137609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD).
    Pouw JN; Leijten EFA; van Laar JM; Boes M
    Clin Exp Immunol; 2021 Feb; 203(2):160-173. PubMed ID: 33090496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keys to unlocking the mysteries of rheumatic autoimmune disease.
    Moser KL; Gaffney P; Peterson E; Behrens T
    Minn Med; 2004 May; 87(5):46-51. PubMed ID: 15191068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases.
    García-González P; Ubilla-Olguín G; Catalán D; Schinnerling K; Aguillón JC
    Autoimmun Rev; 2016 Nov; 15(11):1071-1080. PubMed ID: 27485011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.
    Miao J; Zhu P
    Curr Rheumatol Rep; 2018 Apr; 20(5):30. PubMed ID: 29663162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunodiagnosis of rheumatic diseases].
    Maĭtveĭkov GP; Koshelev VK; Nazarov IuM; Kaliia EC; Dosin IuM
    Ter Arkh; 1981; 53(5):87-93. PubMed ID: 6170125
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
    Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
    Front Immunol; 2021; 12():648408. PubMed ID: 33868284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell therapy for autoimmune diseases: does it have a future?
    Radbruch A; Thiel A
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii96-ii101. PubMed ID: 15479883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and treatment of autoimmune rheumatic diseases.
    Liu E; Perl A
    Curr Opin Rheumatol; 2019 May; 31(3):307-315. PubMed ID: 30920455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tolerogenic dendritic cells by vitamin D receptor agonists.
    Adorini L; Penna G
    Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.